Nimbus Therapeutics Stock
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Sign up today and learn more about Nimbus Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Nimbus Therapeutics Stock
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Funding History
| April 2010 | $3.5M |
|---|---|
| March 2011 | $1.5M |
| June 2011 | $24.0M |
| March 2015 | $43.0M |
| June 2018 | $65.0M |
Management
Chief Business Officer
Jeb Keiper
Head of Chemistry
Ronald Wester
Co-Founder
Bruce Booth
Co-Founder and Director
Ramy Farid
CEO
Donald Nicholson
Head of Nimbus Tyk2
Craig Masse
Chief Scientific Officer
Rosana Kapeller
Head of Nimbus
Donna Romero
Head of Preclinical and Early Development
William Westlin
Head of Nimbus ACC
Geraldine Harriman
Press
Xconomy - Jun, 5 2018
Nimbus Nabs $65M to Advance In-House Drug Discoveries to the ClinicWall Streets Journal - Jun, 5 2018
Nimbus Therapeutics Picks Up Additional $65 MillionEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
